Boric acid vaginal suppositories: A brief review

Prütting, Sylvia; Cerveny, Joli D.

doi:10.1002/(sici)1098-0997(1998)6:4<191::aid-idog10>3.0.co;2-6

Cited by 16 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Boric acid (H 3 BO 3 ), a white, odorless powder, was first used by Lister as a topical antiseptic in 1873 [ 106 ], and has been used in the treatment of vulvovaginal candidiasis [ 107 – 112 ] and Trichomonas vaginalis [ 113 ]. Vaginal boric acid has bacteriostatic and fungistatic action, yet its mechanism of action is unknown [ 114 ]. Boric acid may work on BV through decimation of the vaginal biofilm or change in the acidity of the vagina, while the fungistatic activity may be attributed to fungal cell wall penetration or disruption of the fungal cell membrane [ 115 ].…”

Section: Introductionmentioning

confidence: 99%

Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure

Bradshaw

Brotman

2015

BMC Infect Dis

View full text Add to dashboard Cite

Bacterial vaginosis (BV) is one of the great enigmas in women’s health, a common condition of unknown aetiology, which is associated with significant morbidity and unacceptably high recurrence rates. While it remains unclear whether BV recurrence is predominantly due to failure of current antibiotic regimens to eradicate BV-associated bacteria (BVAB) and biofilm, a failure of some women to re-establish a resilient Lactobacillus-dominant vaginal microbiota, reinfection from sexual partners, or a combination of these factors, it is inherently challenging to make significant inroads towards this goal. In this review, we will outline why BV is such a clinical and epidemiologic conundrum, and focus on several key approaches that we believe merit discussion and clinical research, including strategies to: i) prevent reinfection (partner treatment trials), ii) boost favourable vaginal Lactobacillus species and promote a Lactobacillus-dominant vaginal microbiome (hormonal contraceptive and probiotic trials) and iii) disrupt vaginal BV-associated biofilm.

show abstract

Section: Introductionmentioning

confidence: 99%

Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure

Bradshaw

Brotman

2015

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…They include: Ū Polyhexamethylene biguanide (poliheksanid, PHMB) [2,[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28], Ū Dequaline chloride [2,5,19,20,25,29,31,32], Ū Povidone iodine [33,34], Ū Sliver ions [26,30,[35][36][37][38][39][40], Ū Boric acid [41][42][43][44][45], Ū Chlorhexidine [46][47][48], Ū Lactic acid bacteria with or without estriol [49,50].…”

Section: Introductionmentioning

confidence: 99%

Polish Society of Gynecologists and Obstetricians recommendation on the use of antiseptics for treatment of inflammatory vaginitis

et al. 2020

View full text Add to dashboard Cite

Undertook the analysis of literature, specialist knowledge and clinical experience on treatment options for non-specific vaginal inflammations of bacterial, fungal, mixed and unknown aetiology. The recommendation presents the current state of knowledge on this subject on the day of the published analysis. However, the expert group reserves the right to update this position in the event of new and significant scientific reports.

show abstract

“…Boric acid is a weak inorganic acid and it can be prepared in compounding pharmacies upon medical prescription. Boric acid is seldom used as the first‐line treatment in VVC patients as the conventional antimycotic treatment modalities are considered safer and more effective in treating uncomplicated VVC . However, boric acid treatment may be useful in patients infected by NCAC species or recurrent attacks, especially when the first‐line treatment fails to cure the infections.…”

Section: Introductionmentioning

confidence: 99%

Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches

Chew

Than

2016

Mycoses

View full text Add to dashboard Cite

Vulvovaginal candidosis (VVC) is a common gynaecological disorder that is delineated by the inflammation of vaginal wall and it is caused by the opportunistic fungal pathogen Candida species. In fact, three out of every four women will experience at least one occasion of VVC during some point in their lives. Although uncomplicated VVC is relatively harmless, the complicated VVC such as recurrent attack often creates restlessness and depression in the patients, thus greatly affects their quality of life. Managements of VVC are usually associated with the use of antimycotic suppositories, topical cream or oral agents. These antimycotic agents are either available over-the-counter or prescribed by the clinicians. In recent decades, the rise of clinical challenges such as the increased prevalence of resistant Candida strains, recurrent VVC infection and adverse effects of multidrug interactions have necessitated the development of novel therapeutic or prophylactic options to combat the complicated VVC in the future. In this review, we discuss the current antimycotic treatments available for Candida vaginitis and the problems that exist in these seemingly effective treatments. Besides, we attempt to contemplate some of the future and prospective strategies surrounding the development of alternative therapeutic and prophylactic options in treating and preventing complicated VVC respectively.

show abstract

Boric acid vaginal suppositories: A brief review

Cited by 16 publications

References 17 publications

Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure

Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure

Polish Society of Gynecologists and Obstetricians recommendation on the use of antiseptics for treatment of inflammatory vaginitis

Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches

Contact Info

Product

Resources

About